DPH outlines harm‑reduction strategy as fentanyl drives recent rise in overdose deaths

DPH staff told the Health Commission that death‑reporting lags (to collect toxicology, scene and medical history) produce roughly a 5–6 month delay before complete overdose mortality data are available, and that the department would move from annual to semiannual public reporting to improve situational awareness. Presenters said fentanyl became prominent in the local drug supply in 2018 and that fentanyl‑involved deaths rose substantially in 2019.

DPH described a continuum of harm‑reduction and treatment responses being scaled up: expanded naloxone distribution and refills through syringe access programs (the DOPE Project), fentanyl test strips at syringe sites, the ACDC project to test suspect samples and inform community alerts, low‑barrier buprenorphine via street medicine teams, contingency‑management trials for methamphetamine use disorder and behavioral‑intervention trials (Reboot). The department emphasized site‑level interventions for single‑room occupancy (SRO) hotels, where about one‑third of overdose deaths occur, and a pilot to support tenant‑run overdose prevention programs in those facilities.

DPH staff previewed immediate operational steps: the findtreatment.org portal for real‑time bed availability, expansion of the Hummingbird community model, plans to open a meth sobering center (180 Jones), Project Friend paramedic naloxone take‑home kits, and a 24‑hour sobering center model scheduled for staffing and launch activity in the spring.

Commissioners asked technical questions about methamphetamine‑linked deaths (noting they are often cardiac or cerebrovascular and not reversible by naloxone), whether fentanyl in deaths reflected contamination or intended use (DPH said most fentanyl use appears intentional but some contaminations occur), and the department committed to return with pilot data about points of entry, hours and early outcomes from expanded services.